Product Description
Methacholine Chloride is the chloride salt form of methacholine, a direct-acting cholinergic muscarinic agonist with bronchoconstrictive, miotic, vasodilator, and cardiac vagomimetic activity. Methacholine chloride acts directly on the muscarinic receptors in the heart, eye, and lung, thereby producing parasympathomimetic effects. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Methacholine-chloride)
Mechanisms of Action: mAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | Chile | Denmark | Greece | Israel | Japan | Korea | Norway | Spain | Taiwan | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|